Mirta Acuña, MD

infectious disease MD
Roberto del rio children hospital
Santiago, Region Metropolitana, Chile

Disclosure(s): Pfizer, Janssen, Sanofi, and MSD: Advisor/Consultant, Grant/Research Support, Principal Investigator for Janssen, Sanofi and MSD

Presentation(s):

• 167 - Phase 3, Randomized, Controlled Trial Evaluating Safety, Efficacy, and Pharmacokinetics (PK) of Clesrovimab in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease

  Thursday, October 17, 2024
  2:21 PM – 2:33 PM US PT